Mathieu Felices
Overview
Explore the profile of Mathieu Felices including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
11
Citations
100
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Pasquiers B, Benamara S, Felices M, Ternant D, Decleves X, Puszkiel A
Pharmaceutics
. 2023 Aug;
15(8).
PMID: 37631343
Interspecies translation of monoclonal antibodies (mAbs) pharmacokinetics (PK) in presence of target-mediated drug disposition (TMDD) is particularly challenging. Incorporation of TMDD in physiologically based PK (PBPK) modeling is recent and...
2.
Tarral A, Hovsepian L, Duvauchelle T, Donazzolo Y, Latreille M, Felices M, et al.
Clin Pharmacokinet
. 2023 Feb;
62(3):481-491.
PMID: 36763327
Background And Objectives: Acoziborole is a novel boron-containing candidate developed as an oral drug for the treatment of human African trypanosomiasis (HAT). Results from preclinical studies allowed progression to Phase...
3.
Pasquiers B, Benamara S, Felices M, Nguyen L, Decleves X
Int J Mol Sci
. 2022 Nov;
23(21).
PMID: 36361546
The interest in therapeutic monoclonal antibodies (mAbs) has continuously growing in several diseases. However, their pharmacokinetics (PK) is complex due to their target-mediated drug disposition (TMDD) profiles which can induce...
4.
Dubourg J, Perrimond-Dauchy S, Felices M, Bolze S, Voiriot P, Fouqueray P
Eur J Clin Pharmacol
. 2020 Jun;
76(10):1393-1400.
PMID: 32556539
Purpose: Imeglimin is the first in a new class of oral antidiabetic agents, the glimins, currently in development to improve glycemic control in patients with type 2 diabetes mellitus. A...
5.
Funck-Brentano C, Felices M, Le Fur N, Dubourdieu C, Desche P, Vanhoutte F, et al.
Br J Clin Pharmacol
. 2020 Apr;
86(11):2174-2181.
PMID: 32302009
Aims: We investigated the effect of gadopiclenol, a new gadolinium-based contrast agent, on the QTc interval at clinical and supraclinical dose, considering the relative hyperosmolarity of this product. Methods: This...
6.
Funck-Brentano C, Ouologuem N, Duparc S, Felices M, Sirima S, Sagara I, et al.
Sci Rep
. 2019 Jan;
9(1):883.
PMID: 30696921
Several antimalarial drugs are known to prolong ventricular repolarization as evidenced by QT/QTc interval prolongation. This can lead to Torsades de Pointes, a potentially lethal ventricular arrhythmia. Whether this is...
7.
Funck-Brentano C, Bacchieri A, Valentini G, Pace S, Tommasini S, Voiriot P, et al.
Sci Rep
. 2019 Jan;
9(1):777.
PMID: 30692558
QT/QTc interval prolongation reflects delayed cardiac repolarization which can lead to Torsade de Pointes and sudden death. Many antimalarial drugs prolong QT/QTc interval. However, due to confounding factors in patients...
8.
Scala M, Koob M, de Buttet S, Bourrinet P, Felices M, Jurkiewicz E
Invest Radiol
. 2017 Sep;
53(2):70-79.
PMID: 28906338
Objectives: The primary objective of this study was to investigate the pharmacokinetic profile of gadoterate meglumine in pediatric patients younger than 2 years; the secondary objectives were to document its...
9.
Tarral A, Blesson S, Valverde Mordt O, Torreele E, Sassella D, Bray M, et al.
Clin Pharmacokinet
. 2014 Feb;
53(6):565-80.
PMID: 24535888
Background And Objectives: Fexinidazole is a 5-nitroimidazole recently included in a clinical efficacy trial as an oral drug for the treatment of human African trypanosomiasis (HAT). Preclinical studies showed it...
10.
Charpentier C, Lambert-Niclot S, Larrouy L, Peytavin G, Valantin M, Landman R, et al.
J Acquir Immune Defic Syndr
. 2011 Jul;
57(1):e15-7.
PMID: 21734472
No abstract available.